K-M Myhr
Overview
Explore the profile of K-M Myhr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1237
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Storm-Larsen C, Myhr K, Farbu E, Midgard R, Nyquist K, Broch L, et al.
Mult Scler J Exp Transl Clin
. 2019 Dec;
5(4):2055217319888767.
PMID: 31798939
Introduction: Patients with multiple sclerosis may have a distinct gut microbiota profile. Delayed-release dimethyl fumarate is an orally administered drug for relapsing-remitting multiple sclerosis, which has been associated with gastrointestinal...
2.
Svendsen B, Grytten N, Bo L, Aarseth H, Smedal T, Myhr K
Eur J Health Econ
. 2018 Apr;
19(9):1243-1257.
PMID: 29680926
Background: Multiple sclerosis (MS) imposes high economic costs on society, but the patients and their families have to bear some of these costs. Objective: We aimed to estimate the magnitude...
3.
Olberg H, Eide G, Cox R, Jul-Larsen A, Lartey S, Vedeler C, et al.
Eur J Neurol
. 2017 Dec;
25(3):527-534.
PMID: 29205701
Background And Purpose: We have previously shown that patients with multiple sclerosis receiving immunomodulatory treatment have reduced seroprotection rates after influenza immunization. The aim of this study was to further...
4.
Wergeland S, Myhr K, Loken-Amsrud K, Beiske A, Bjerve K, Hovdal H, et al.
Eur J Neurol
. 2016 Mar;
23(6):1064-70.
PMID: 26998820
Background And Purpose: Our objective was to study the association between serum levels of anti Epstein-Barr virus nuclear antigen 1 (EBNA-1) antibody and 25-hydroxyvitamin D (25(OH)D) in a prospective cohort...
5.
Torkildsen O, Myhr K, Bo L
Eur J Neurol
. 2015 Nov;
23 Suppl 1:18-27.
PMID: 26563094
Background And Purpose: There is still no curative treatment for multiple sclerosis (MS), but during the last 20 years eight different disease-modifying compounds have been approved for relapsing-remitting MS (RRMS)....
6.
Goulden R, Riise T, Myhr K, Pugliatti M, Wolfson C
Eur J Neurol
. 2015 Oct;
23(1):168-74.
PMID: 26475404
Background And Purpose: The findings from existing research on the association between socioeconomic status (SES) and multiple sclerosis (MS) are inconsistent. Most previous studies are limited to one country and...
7.
Grytten N, Torkildsen O, Myhr K
Acta Neurol Scand
. 2015 Jun;
132(199):29-36.
PMID: 26046556
Norway has been subjected to numerous epidemiological investigations on the prevalence and incidence of multiple sclerosis (MS), dating back to 1935. The objective of this study was to review the...
8.
Myhr K, Grytten N, Torkildsen O, Wergeland S, Bo L, Aarseth J
Acta Neurol Scand
. 2015 Jun;
132(199):24-8.
PMID: 26046555
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system with unknown cause and various benefits from disease modifying therapies. Systematic recording of data into national MS...
9.
Holmoy T, Esbensen Q, Torkildsen O, Wergeland S, Bjerve K, Beiske A, et al.
Acta Neurol Scand
. 2015 Jun;
133(4):309-12.
PMID: 26037530
Background: It has been suggested that polymorphisms in the WT1 gene modulate the effect of IFN-β treatment in multiple sclerosis (MS) through regulation of the relationship between IFN-β and vitamin...
10.
Klevan G, Jacobsen C, Aarseth J, Myhr K, Nyland H, Glad S, et al.
Acta Neurol Scand
. 2013 Jun;
129(1):21-6.
PMID: 23772958
Objective: To describe a representative population of patients recently diagnosed with MS in terms of both motor and non-motor disability. In particular we wanted to examine the HRQoL in this...